A recent systematic review assessing GLP-1 receptor agonists in AD found that, while these agents do not appear to significantly improve cognitive function via effects on amyloid-β and tau biomarkers, they may still offer metabolic and neuroprotective benefits [64]. Here, MAPT is linked to Alzheimer disease.